MedTrace Logo

Lifemel Honey to Reduce Leucopenia During Chemotherapy

NCT00243165 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-12-07

No results posted yet for this study

Summary

This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity.

Conditions

Interventions

BEHAVIORAL

Lifemel honey intake every day

Sponsors & Collaborators

  • Zuf Globus Laboratories Ltd.

    collaborator OTHER

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Georgeta Fried, MD · Rambam Health Care Campus

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243165 on ClinicalTrials.gov